Calcium and vitamin D supplementation are necessary as treatments for osteoporosis, while the main drugs currently available include estrogen, selective estrogen receptor modulators (e.g., raloxifene), calcitonin, bisphosphonates (e.g., alendronate, risedronate, ibandronate, and zoledronic acid), parathyroid hormone analogue (e.g., teriparatide), and receptor activator of nuclear factor-kB ligand (RANKL) monoclonal antibody (e.g., denosumab) (9, 10). Here, TNFSF11 is linked to osteoporosis.